{
    "body": "Intetumumab has been tested in clinical trials for treatment of which cancers?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21750555", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23104724", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22027908", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20145975", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21331745"
    ], 
    "ideal_answer": [
        "Intetumumab has been tested in clinical trials for treatment of prostate cancer, melanoma and angiosarcoma."
    ], 
    "exact_answer": [
        [
            "prostate cancer"
        ], 
        [
            "melanoma"
        ], 
        [
            "angiosarcoma"
        ]
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016430"
    ], 
    "type": "list", 
    "id": "550e866271445a662f000005", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 261, 
            "text": "A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human \u03b1\u03bd integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23104724", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 476, 
            "text": "BACKGROUND: Intetumumab is a fully human mAb with antiangiogenic, antitumor properties which has shown potential therapeutic effect in castration-resistant prostate cancer (CRPC) patients. PATIENTS AND METHODS: In a phase 2, randomized, double-blind, multicenter study, men with metastatic CRPC without prior systemic nonhormonal therapy were randomly assigned to 75-mg/m(2) docetaxel (Taxotere) and 5-mg prednisone plus placebo (N = 65) or 10-mg/kg intetumumab (N = 66) q3w. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23104724", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1605, 
            "offsetInEndSection": 1730, 
            "text": "CONCLUSION: The addition of intetumumab to docetaxel resulted in shorter PFS without additional toxicity among CRPC patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23104724", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 220, 
            "offsetInEndSection": 491, 
            "text": "Data from the Melanoma Subscale (MS) of the Functional Assessment of Cancer Therapy-Melanoma and the worst pain question from the Brief Pain Inventory (BPI) were taken from a clinical trial evaluating intetumumab alone or with dacarbazine in Stage IV metastatic melanoma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22027908", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 118, 
            "text": "A randomised, phase II study of intetumumab, an anti-\u03b1v-integrin mAb, alone and with dacarbazine in stage IV melanoma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750555", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1523, 
            "offsetInEndSection": 1680, 
            "text": "CONCLUSION: With its favourable safety profile and a nonsignificant trend towards improved OS, intetumumab merits further investigation in advanced melanoma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750555", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 164, 
            "offsetInEndSection": 446, 
            "text": "METHODS: In a multicentre, randomised, phase II study, stage IV melanoma patients were randomised 1:1:1:1 to 1000 mg m(-2) dacarbazine+placebo (n=32), 1000 mg m(-2) dacarbazine+10 mg kg(-1) intetumumab (n=32), 10 mg kg(-1) intetumumab (n=33), or 5 mg kg(-1) intetumumab (n=32) q3w. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750555", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 124, 
            "text": "Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331745", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 559, 
            "text": "PURPOSE: In this Phase 1, multicenter, open-label study, intetumumab (CNTO 95), a fully human anti-\u03b1v integrin monoclonal antibody was evaluated for safety, pharmacokinetics, and pharmacodynamic activity in patients with melanoma or angiosarcoma. PATIENTS AND METHODS: Patients with histologically-confirmed inoperable melanoma or angiosarcoma refractory to standard treatment were allocated to treatment with 10 mg/kg or 20 mg/kg intetumumab, administered once every 3 weeks for up to four cycles unless unacceptable toxicity or disease progression occurred.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331745", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1546, 
            "offsetInEndSection": 1803, 
            "text": "CONCLUSIONS: In patients with metastatic malignant melanoma and angiosarcoma in this study, intetumumab demonstrated manageable toxicity, was well tolerated, and presented approximately dose-proportional pharmacokinetics for the 10 mg/kg and 20 mg/kg doses.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331745", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 251, 
            "text": "A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human \u03b1(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20145975", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 449, 
            "text": "PURPOSE: We evaluated the safety and efficacy of intetumumab in combination with docetaxel in patients with castrate-resistant metastatic prostate cancer. Patients and methods In this phase 1, open-label, multicenter, nonrandomized study, 75 mg/m\u00b2 docetaxel was administered on Day 1 of each of nine 21-day treatment cycles and intetumumab 5 or 10 mg/kg was administered on Days 1, 8, and 15 of Cycles 2 and 3 and on Day 1 of all subsequent cycles. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20145975", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 149, 
            "offsetInEndSection": 421, 
            "text": "In a multicentre, randomised, phase II study, stage IV melanoma patients were randomised 1:1:1:1 to 1000 mg m(-2) dacarbazine+placebo (n=32), 1000 mg m(-2) dacarbazine+10 mg kg(-1) intetumumab (n=32), 10 mg kg(-1) intetumumab (n=33), or 5 mg kg(-1) intetumumab (n=32) q3w.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21750555", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 236, 
            "offsetInEndSection": 526, 
            "text": "Patients with histologically-confirmed inoperable melanoma or angiosarcoma refractory to standard treatment were allocated to treatment with 10 mg/kg or 20 mg/kg intetumumab, administered once every 3 weeks for up to four cycles unless unacceptable toxicity or disease progression occurred.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21331745", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 218, 
            "offsetInEndSection": 490, 
            "text": "Data from the Melanoma Subscale (MS) of the Functional Assessment of Cancer Therapy-Melanoma and the worst pain question from the Brief Pain Inventory (BPI) were taken from a clinical trial evaluating intetumumab alone or with dacarbazine in Stage IV metastatic melanoma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22027908", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 219, 
            "offsetInEndSection": 489, 
            "text": "Data from the Melanoma Subscale (MS) of the Functional Assessment of Cancer Therapy-Melanoma and the worst pain question from the Brief Pain Inventory (BPI) were taken from a clinical trial evaluating intetumumab alone or with dacarbazine in Stage IV metastatic melanoma", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22027908", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 220, 
            "offsetInEndSection": 490, 
            "text": "Data from the Melanoma Subscale (MS) of the Functional Assessment of Cancer Therapy-Melanoma and the worst pain question from the Brief Pain Inventory (BPI) were taken from a clinical trial evaluating intetumumab alone or with dacarbazine in Stage IV metastatic melanoma", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22027908", 
            "endSection": "abstract"
        }
    ]
}